Orally delivered compounds selectively modify RNA splicing, prevent deficits in SMA models

Results published in Science show small molecule SMN2 splicing modifiers to be effective in SMA mouse models

2014-08-07

(Press-News.org) Today the journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing deficits in a mouse model of Spinal Muscular Atrophy (SMA). Scientists from Roche Pharma Research and Early Development (pRED), PTC Therapeutics, Inc., the SMA Foundation, the University of Southern California and Harvard University collaborated to demonstrate that continuous treatment of SMA mice with these compounds increased life span, normalized body weight and prevented both disease-related motor dysfunction and neuromuscular deficits. To view the animation related to the study, please visit: http://youtu.be/Fp7MQlZGpKI.

"Although still preclinical, these results demonstrate how SMN2 splicing modifiers could correct the molecular deficit that causes SMA," said Luca Santarelli, Head of Neuroscience, Ophthalmology and Rare Diseases at Roche. "This study represents an important step towards developing a potential therapeutic option for this devastating and currently untreatable condition. Early clinical trials are currently underway to determine the safety and tolerability of this approach."

"The investigational compounds used in this study represent the first orally available SMN2 splicing modifiers for SMA," commented Stuart W. Peltz, CEO of PTC Therapeutics, Inc. "Using the experience and expertise in RNA biology we have gained at PTC over the last 16 years, we used our alternative splicing technology to identify and subsequently optimize investigational compounds that target the SMN2 splicing to produce the SMN protein. Our unique partnership with Roche and the SMA Foundation has allowed this project to rapidly move into clinical development."

The study used chemical screening and optimization to identify orally available small molecules that selectively alter the splicing of the SMN2 pre-mRNA to produce stable full-length SMN protein. The SMN2 splicing modifiers described in the Science article penetrated into all mouse tissues tested, including brain, spinal cord and muscle, and thus improved SMN2 RNA splicing to increase SMN protein production in these disease-relevant tissues. As a result of the SMN protein increase, the compounds prevented the progression of SMA in a severe mouse model. These compounds also corrected SMN2 RNA splicing and increased SMN protein levels in cell cultures obtained from SMA patients, including stem cell-derived motor neurons. A Phase I clinical program to assess safety and tolerability with investigational compounds was initiated in early 2014.

"The findings of this preclinical study contribute significantly to our understanding of SMA and provide further evidence suggesting that our strategy to upregulate SMN with small molecules could be effective," said Loren Eng, President of the SMA Foundation. "We are proud to have seeded this important work – we believe it could have a meaningful impact on the lives of patients who suffer from SMA."

SMA is a genetic disease caused by mutation or deletion of the SMN1 (survival of motor neuron) gene. It affects one in approximately 10,000 live births and in the most severe forms is associated with a high rate of childhood mortality. SMA is characterized by progressive loss of motor neurons, muscle weakness and atrophy. The disease affects mainly proximal muscles including intercostal muscles (chest muscles), and patients often die due to respiratory complications.

INFORMATION: About The SMA Foundation Founded in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment for Spinal Muscular Atrophy through targeted funding of clinical research and novel drug development efforts. Since its inception, the Foundation has awarded over $100 million for SMA research. The SMA Foundation serves as the hub and clearinghouse of information for the diverse universes involved in drug development, including pharmaceutical and biotech companies, academia, non-profits, clinicians, patients, government/regulators, and the media. In addition, the Foundation is committed to raising awareness and generating support for increased research efforts in SMA among the leaders of industry and government. For more information, visit the SMA Foundation website at http://www.smafoundation.org.

About PTC Therapeutics PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and in collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website http://www.ptcbio.com.

About Roche Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority stakeholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com.

Roche Pharma Research and Early Development Communications, Basel, Switzerland Zuzana Dobbie
Phone: +1-41-61-688-8268
E-mail: zuzana.dobbie_graf@roche.com

PTC Therapeutics, Inc. Jane Baj
Phone: +1 (908) 912-9167
E-mail: jbaj@ptcbio.com

SMA Foundation
Sergey Paushkin, M.D., Ph.D.
Phone:+1 (646) 253-7100 E-mail: spaushkin@smafoundation.org

ELSE PRESS RELEASES FROM THIS DATE:

Study reveals dynamics of microbes and nitrate

2014-08-07

Human tampering with global carbon balances has received massive public attention because of its effects on global warming, but we pay less attention to another set of chemical processes we are similarly disrupting: human input to the nitrogen cycle. Unfortunately, the story of nitrogen transformations in the biosphere is also less understood. In modern times, humans developed the technology to turn nitrogen gas in the atmosphere into a biologically available form to be used as fertilizer. Before this, bio-available or "fixed" nitrogen was only created sparingly by natural ...

Origami could lead to exotic materials, tiny transformers

2014-08-07

ITHACA, N.Y. – Embracing the pleats, creases and tucks of the Japanese art of decorative paper folding, Cornell University researchers are uncovering how origami principles could lead to exotic materials, soft robots and even tiny transformers. Publishing online in the journal Science Aug. 8, an interdisciplinary team led by Cornell's Itai Cohen, associate professor of physics, and graduate student Jesse Silverberg have discovered how to use a well-known origami folding pattern called the Miura-ori to control fundamental physical properties of any thin sheet of material. Video, ...

Step closer to birth of the sun

2014-08-07

Researchers are a step closer to understanding the birth of the sun. Published in Science, the team led by Dr Maria Lugaro and Professor Alexander Heger, from Monash University, have investigated the solar system's prehistoric phase and the events that led to the birth of the sun. Dr Lugaro, from the Monash Centre for Astrophysics, said the team used radioactivity to date the last time that heavy elements such as gold, silver, platinum, lead and rare-earth elements were added to the solar system matter by the stars that produced them. "Using heavy radioactive nuclei ...

Finding the genetic culprits that drive antibiotic resistance

2014-08-07

Researchers have developed a powerful new tool to identify genetic changes in disease-causing bacteria that are responsible for antibiotic resistance. The results from this technique could be used in clinics within the next decade to decide on the most effective treatments for diseases such as pneumonia and meningitis. The team looked at the genome of Streptococcus pneumoniae, a bacterial species that causes 1.6 million deaths worldwide each year. In the most detailed research of its kind, scientists used a genome-wide association study (GWAS) to locate single-letter ...

Learning from origami to design new materials

2014-08-07

AMHERST, Mass. -- A challenge increasingly important to physicists and materials scientists in recent years has been how to design controllable new materials that exhibit desired physical properties rather than relying on those properties to emerge naturally, says University of Massachusetts Amherst physicist Christian Santangelo. Now he and physicist Arthur Evans and polymer scientist Ryan Hayward at UMass Amherst, with others at Cornell and Western New England University, are using origami-based folding methods for "tuning" the fundamental physical properties of any ...

Robot folds itself up and walks away

2014-08-07

A team of engineers used little more than paper and Shrinky dinks™ – the classic children's toy that shrinks when heated – to build a robot that assembles itself into a complex shape in four minutes flat, and crawls away without any human intervention. The advance, described in Science, demonstrates the potential to quickly and cheaply build sophisticated machines that interact with the environment, and to automate much of the design and assembly process. The method draws inspiration from self-assembly in nature, such as the way linear sequences of amino acids fold into ...

Origami robot folds itself up, crawls away

2014-08-07

For years, a team of researchers at MIT and Harvard University has been working on origami robots — reconfigurable robots that would be able to fold themselves into arbitrary shapes. In the August 7 issue of Science, they report their latest milestone: a robot, made almost entirely from parts produced by a laser cutter, that folds itself up and crawls away as soon as batteries are attached to it. "The exciting thing here is that you create this device that has computation embedded in the flat, printed version," says Daniela Rus, the Andrew and Erna Viterbi Professor ...

NASA sees heavy rainfall in Iselle as the hurricane nears Hawaii

2014-08-07

VIDEO: TRMM satellite rainfall data overlaid on an enhanced infrared image from NOAA's GOES-West satellite shows heavy rainfall occurring around the Iselle's eye. The most intense rain was falling at a... Click here for more information. A NASA satellite has observed heavy rainfall in Hurricane Iselle on its approach to Hawaii. NASA's TRMM Satellite captured rainfall rates within the storm as it passed overhead. In addition, NASA's Aqua satellite provided a larger view of the Central ...

Cell signaling pathway linked to obesity, type 2 diabetes

2014-08-07

WEST LAFAYETTE, Ind. - A Purdue University study shows that Notch signaling, a key biological pathway tied to development and cell communication, also plays an important role in the onset of obesity and Type 2 diabetes, a discovery that offers new targets for treatment. A research team led by Shihuan Kuang, associate professor of animal sciences, found that blocking Notch signaling in the fat tissue of mice caused white fat cells to transform into a "leaner" type of fat known as beige fat. The finding suggests that suppressing Notch signaling in fat cells could reduce ...

Gut microbes browse along a gene buffet

2014-08-07

DURHAM, N.C. -- In the moist, dark microbial rainforest of the intestine, hundreds of species of microorganisms interact with each other and with the cells of the host animal to get the resources they need to survive and thrive. Though there's a lot of competition in this vibrant ecosystem, collaboration is valued too. A new study on the crosstalk between microbes and cells lining the gut of mice shows just how cooperative this environment can be. One of the main ways that hosts manage their interactions with microbes is by carefully controlling the genes that their ...

Orally delivered compounds selectively modify RNA splicing, prevent deficits in SMA models

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: